Clinical trials: CIN1
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia
Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022
In France, the screening rate for cervical cancer remains too low. Screening is simple and non-invasive. Pregnant patients are most of the time young and are part of the target population for screening, and for many women, it is…
- Trial name
- NCT05595252
- Testing
- cervical biopsy
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia
Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1
This study looks at immediate treatment of a cervix with CIN 1 versus regular six-month follow-up with colposcopy and treatment if CIN 1 progresses.
- Trial name
- NCT00156026
- Testing
- loop electrosurgical excision procedure (LEEP)
- Where
- 10 sites in Brazil, Canada
- Volunteers
- 415 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Precancerous Condition
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of diindolylmethane, a substance found in cruciferous vegetables, may keep cervical intraepithelial neoplasia or cervical cancer from…
- Trial name
- NCT00462813
- Testing
- oral microencapsulated diindolylmethane, polymerase chain reaction, cervical Papanicolaou test
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Barts and the London School of Medicine and Dentistry
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.